Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Bhalla

Showing results (131-140 of 189) with videos related to

Pageof 19
Sort By:
Blood|July 30, 2009
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cellsWarren Fiskus, Yongchao Wang, Arun Sreekumar, et al.
Breast Cancer Research and Treatment|June 18, 2017
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)Lori J Goldstein, Fengmin Zhao, Molin Wang, et al.
Cancer Research|July 5, 2006
RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancerQuek Choon Lau, Erna Raja, Manuel Salto-Tellez, et al.
Blood|December 17, 2008
Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanismJianguang Chen, Warren Fiskus, Kelly Eaton, et al.
Nature Medicine|December 8, 2009
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomasLeandro C Cerchietti, Eloisi C Lopes, Shao Ning Yang, et al.
Leukemia|February 7, 2013
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignanciesD J DeAngelo, A Spencer, K N Bhalla, et al.
Leukemia|September 29, 2016
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cellsDyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
Nature Medicine|April 3, 2024
Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomasLeandro C Cerchietti, Eloisi C Lopes, Shao Ning Yang, et al.
Blood|July 2, 2011
Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1Ramesh Balusu, Warren Fiskus, Rekha Rao, et al.
Blood|August 9, 2015
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinibBaohua Sun, Bhavin Shah, Warren Fiskus, et al.
Pageof 19

Showing results (131-140 of 189) with videos related to

Sort By:
Pageof 19
Blood|July 30, 2009
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cellsWarren Fiskus, Yongchao Wang, Arun Sreekumar, et al.
Breast Cancer Research and Treatment|June 18, 2017
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)Lori J Goldstein, Fengmin Zhao, Molin Wang, et al.
Cancer Research|July 5, 2006
RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancerQuek Choon Lau, Erna Raja, Manuel Salto-Tellez, et al.
Blood|December 17, 2008
Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanismJianguang Chen, Warren Fiskus, Kelly Eaton, et al.
Nature Medicine|December 8, 2009
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomasLeandro C Cerchietti, Eloisi C Lopes, Shao Ning Yang, et al.
Leukemia|February 7, 2013
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignanciesD J DeAngelo, A Spencer, K N Bhalla, et al.
Leukemia|September 29, 2016
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cellsDyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
Nature Medicine|April 3, 2024
Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomasLeandro C Cerchietti, Eloisi C Lopes, Shao Ning Yang, et al.
Blood|July 2, 2011
Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1Ramesh Balusu, Warren Fiskus, Rekha Rao, et al.
Blood|August 9, 2015
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinibBaohua Sun, Bhavin Shah, Warren Fiskus, et al.
Pageof 19